GS87 demonstrates efficacy in a circulating AML mouse model system.

Slides:

Advertisements

Similar presentations

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

Advertisements

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.

Morphological analyses of peripheral blood and bone marrow cells isolated from leukemic mice. Morphological analyses of peripheral blood and bone marrow.

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

Effects of senescent cells on activity.

AZD7762 abrogated the G2 checkpoint in a novel hollow fiber assay.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Effects of SC144 on in vivo ovarian tumor.

BV6 increases tumor burden in bone.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Cytotoxic activities of polymer micelles containing CFZ in H460 (A) and select micelle formulations in RPMI-8226 (B) cell lines. Cytotoxic activities of.

Cytotoxic effects of PM1 and PM2 empty particle controls and coincubation of CFZ with empty particles tested in H460 (A) and RPMI-8226 (B) cells. Cytotoxic.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Activity of MAC-321 (i. v. and p. o

A, IC50 dose–response curves of SYD985, T-DM1, and ADC isotype control in all USC cell lines tested in vitro (i.e., HER2 3+ cell lines, P =

Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells. Apoptosis induced by ssHHT in HL60 and its derivative, the HL60/MRP, cells.

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control hamster Ig–and.

Protection from 4T1 tumor rechallenge in treated mice.

GA blocks HIF activity and reduces HIF target expression.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

Effects of PS-341 on apoptosis in orthotopic human pancreatic tumors.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Expression analysis of IGFBP-3 using human whole-genome microarray.

Skin tumor size following ligand activation of PPARβ/δ and inhibition of COX2. Skin tumor size following ligand activation of PPARβ/δ and inhibition of.

Gramicidin A (GA) decreases HIF protein expression in RCC cells.

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

Protracted temozolomide (TMZ) treatment leads to acquired TMZ resistance in glioblastoma (GBM) cells in vivo. Protracted temozolomide (TMZ) treatment leads.

Leukemic blasts express a “hypoxia signature

Effect of HA on hematopoietic recovery in tumor-bearing mice.

PTENP1 sensitizes renal cancer cells to chemotherapy.

EGCG inhibits cell survival and growth of EFT cell lines but not of HBMECs. A, dose-responsive curves of fractional survival of EFT cells (TC32 and TC71)

NSG mice transplanted with human primary ALK-positive ALCL tumor grafts were administered either doxorubicin, 10 mg/kg i.v. or CEP orally, 100 mg/kg,

Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea and weight loss. Tlr4−/− attenuates symptomatic parameters of gut toxicity: diarrhea.

Aberrant cytokine production in CD45. 2-mutant and CD45

SBC-5 miR-335+ xenografts abrogated completely, or in part, skeletal osteolytic lesions in humanized NOD/SCID IL2Rγnull immunodeficient mice. SBC-5 miR-335+

Survival and tumor burden of mice bearing peritoneally disseminated gastric cancer. Survival and tumor burden of mice bearing peritoneally disseminated.

TSA-mediated changes in cell cycle inhibitor proteins.

Effect of therapy with S247 on the development of liver metastases after 14 and 21 days of tumor growth. Effect of therapy with S247 on the development.

Endothelial cells/microvasucles are increased in prostate cancer versus normal tissues. Endothelial cells/microvasucles are increased in prostate cancer.

In vivo efficacy of targeted EDVTM in an orthotopic neuroblastoma mouse model with high EGFR protein levels. In vivo efficacy of targeted EDVTM in an orthotopic.

Antitumor effects of celastrol in vitro and in vivo.

In vivo AraC treatment does not induce any consistent changes in CD34+/−CD38+/− phenotypes nor in quiescent leukemic cells but increases apoptotic cell.

Flow cytometric analysis of ROS production in oligonucleotide-treated PC3 prostate cancer cells as demonstrated by the oxidation of H2DCF → DCF and HE.

GS87 is a highly specific and potent GSK3 inhibitor that induces AML cell differentiation. GS87 is a highly specific and potent GSK3 inhibitor that induces.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

A, P causes G2-M arrest with apoptosis in asynchronous population of PC-3 when exposed to 1.5 and 5 μmol/L P for various time points. A, P

ESKM treatment does not affect leukocyte or HSC counts in HLA-A

A, tumor growth studies in H1975 tumor–bearing mice.

SY-1425 induces maturation in RARA-high AML

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

WP1066 inhibits the progression of OCIM2 cells through the cell cycle.

Activity of a chemically modified miR-21 inhibitor in human bladder cancer xenografts. Activity of a chemically modified miR-21 inhibitor in human bladder.

Systemic reovirus treatment targets disseminated human myeloma in vivo

Association of overall survival and PAP-specific (A, B) and PA2024-specific (C, D) CTL activity at week 26 using categorical (tertile) analysis and continuous.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Effects of ZOL treatment on pulmonary metastases.

BV6 increases bone metastasis.

In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B cells harboring Jak3V670A. In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B.

BH3-targeted inhibitors drive specific resistance in human cell lines, which can be overcome with alternating or combining inhibitors. BH3-targeted inhibitors.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

Inhibition of MCL1 reduces AML in an in vivo murine model.

AXL knockout does not prevent dormancy.

E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated.

Presentation transcript:

GS87 demonstrates efficacy in a circulating AML mouse model system. GS87 demonstrates efficacy in a circulating AML mouse model system. A, mice treated with GS87 showed longer survival compared with those treated with vehicle or the standard AML therapeutic cytarabine in a mouse model of human primary AML. B, bone marrow blast percentage in mice with primary human AML sacrificed because of moribund state or at study endpoint of 90 days showed significantly higher percentage of blasts in the vehicle and cytarabine groups compared with the GS87 group. Note: the GS87 mice tested were the surviving mice at the end of the study period. C and D, mouse model of circulating HL-60 cells showing a reduced disease burden in the bone marrow (C) and evidence of AML differentiation (D) in the GS87-treated mice. Sophia Hu et al. Mol Cancer Ther 2016;15:1485-1494 ©2016 by American Association for Cancer Research